Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Non-Small Cell Lung Cancers

(2015) Y.-C. Lin et al.   CLINICAL CANCER RESEARCH

Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach

(2015) Lihui Wang et al.   Oncotarget

Taxanes, past, present, and future impact on non-small cell lung cancer

(2014) Monika Joshi et al.   ANTI-CANCER DRUGS

nab-Paclitaxel for the Treatment of Advanced Squamous Non–Small-Cell Lung Cancer: A Comprehensive Update

(2014) George R. Simon   Clinical Lung Cancer

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

(2014) M.A. Socinski   Current Oncology

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition

(2014) Darren M. Hutt et al.   PLoS One

Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells

(2014) Shereen Jamaladdin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation

(2014) Y Huang et al.   Cell Death & Disease

Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-α-mediated signaling

(2014) X Peng et al.   Cell Death & Disease

Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer

(2013) Alpana Ray et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Management of non-small-cell lung cancer: recent developments

(2013) Martin Reck et al.   LANCET

Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression

(2013) M C C Sachweh et al.   Cell Death & Disease

Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition

(2012) Reecha D. Shah et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

HDAC inhibitor-based therapies: Can we interpret the code?

(2012) Maria New et al.   Molecular Oncology

Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells

(2012) G M A Ajabnoor et al.   Cell Death & Disease

Sensitization of tumor cells by targeting histone deacetylases

(2011) Paola Perego et al.   BIOCHEMICAL PHARMACOLOGY

Src family kinases and paclitaxel sensitivity

(2011) Xiao-Feng Le et al.   CANCER BIOLOGY & THERAPY

Role for Class I histone deacetylases in multidrug resistance

(2011) Yichun Xu et al.   EXPERIMENTAL CELL RESEARCH

Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation

(2010) O. M. Dovey et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2009) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY